论文部分内容阅读
增生性玻璃体视网膜病变(PVR)是裂孔性和外伤性视网膜脱离及视网膜手术复位后的严重并发症,也是造成手术失败和患者视力丧失的主要原因。各种抗增生药物是辅助玻璃体手术治疗PVR的有效途径,缓释系统的应用不但使药物在玻璃体腔内能以有效浓度缓慢持续发挥效应,而且实现了多种抗增生药物的联合应用,针对性地作用于PVR不同病理过程,大大提高了药物疗效,同时,也减少了抗增生药对眼内组织的毒副作用。
Proliferative vitreoretinopathy (PVR) is a serious complication of debridement and traumatic retinal detachment and retinal reattachment, and is also the main reason for the failure of surgery and the loss of vision in patients. A variety of anti-proliferative drugs is an effective way to assist vitreous surgery in the treatment of PVR. The application of the sustained-release system not only enables the drug to slowly and continuously exert its effect in the vitreous cavity at an effective concentration, but also realizes the combination and application of various anti-proliferative drugs Acting on different pathological processes of PVR, greatly improving the efficacy of the drug, meanwhile, it also reduces the toxic side effects of the anti-proliferative drug on the eye tissue.